Ana Sebio相关文献与解析，生知库 | 链接生命科学的每一步

Anna C Virgili, Juliana Salazar, Alberto Gallardo, Antonio López-Pousa, Raúl Terés, Silvia Bagué, Ruth Orellana, Caterina Fumagalli, Ramon Mangues, Lorena Alba-Castellón, Ugutz Unzueta, Isolda Casanova, Ana Sebio

肿瘤

发表日期：2024

文献求助收藏

[Respiratory physiotherapy in post-COVID-19: a decision-making algorithm for clinical practice]

[新冠肺炎后呼吸物理治疗：临床实践决策算法]

期刊:Open Respiratory Archives

影响因子:

doi:10.1016/j.opresp.2021.100139

Arbillaga-Etxarri, Ane; Lista-Paz, Ana; Alcaraz-Serrano, Victoria; Escudero-Romero, Raúl; Herrero-Cortina, Beatriz; Balañá Corberó, Ana; Sebio-García, Raquel; Vilaró, Jordi; Gimeno-Santos, Elena

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report

孤立性纤维瘤中新型 NFIX-STAT6 基因融合：病例报告

期刊:International Journal of Molecular Sciences

影响因子:0.7

doi:10.3390/ijms22147514

David S Moura, Juan Díaz-Martín, Silvia Bagué, Ruth Orellana-Fernandez, Ana Sebio, Jose L Mondaza-Hernandez, Carmen Salguero-Aranda, Federico Rojo, Nadia Hindi, Christopher D M Fletcher, Javier Martin-Broto

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

ABCB1 基因变异可预测转移性结直肠癌患者伊立替康诱发的严重胃肠道毒性

期刊:Frontiers in Pharmacology

影响因子:4.4

doi:10.3389/fphar.2020.00973

Pau Riera, Alícia Artigas-Baleri, Juliana Salazar, Ana Sebio, Anna C Virgili, María Jesús Arranz, David Páez

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

药物基因组学临床随机 II 期试验，根据转移性结直肠癌患者的 UGT1A 1 基因型评估 FOLFIRI 与高剂量伊立替康 (HD-FOLFIRI) 的疗效和安全性

期刊:British Journal of Cancer

影响因子:6.4

doi:10.1038/s41416-018-0348-7

David Páez, María Tobeña, Julen Fernández-Plana, Ana Sebio, Anna C Virgili, Lluís Cirera, Agustí Barnadas, Pau Riera, Ivana Sullivan, Juliana Salazar

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

人类癌症中假定的 DNA/RNA 解旋酶 SLFN11 的表观遗传失活导致对铂类药物的耐药性

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.6413

Vanesa Nogales, William C Reinhold, Sudhir Varma, Anna Martinez-Cardus, Catia Moutinho, Sebastian Moran, Holger Heyn, Ana Sebio, Agusti Barnadas, Yves Pommier, Manel Esteller

CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas

CXCR4 表达作为软组织肉瘤的预后生物标志物

[Respiratory physiotherapy in post-COVID-19: a decision-making algorithm for clinical practice]

[新冠肺炎后呼吸物理治疗：临床实践决策算法]

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report

孤立性纤维瘤中新型 NFIX-STAT6 基因融合：病例报告

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

ABCB1 基因变异可预测转移性结直肠癌患者伊立替康诱发的严重胃肠道毒性

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

药物基因组学临床随机 II 期试验，根据转移性结直肠癌患者的 UGT1A 1 基因型评估 FOLFIRI 与高剂量伊立替康 (HD-FOLFIRI) 的疗效和安全性

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

人类癌症中假定的 DNA/RNA 解旋酶 SLFN11 的表观遗传失活导致对铂类药物的耐药性